A new study that is yet to be peer-reviewed has found that rats given psilocybin injections immediately after suffering minor brain injuries can not only recover from their injuries but also strengthen neural connections within the brain.
To arrive at these findings, the researchers used female rats as study subjects. The rats were subjected to mild head blows on a daily basis for 3 days to simulate simple traumatic brain injuries. After 3 days of these blows, the rats were divided into two groups. One group was given a saline solution while the other group received psilocybin injections. The group given the saline solution served as the control group.
MRI scans were then conducted on the brains of all the rats. The rats treated with the saline solution had vasogenic edema. The psilocybin-treated group exhibited mild vasogenic edema. Additionally, the group that received the psilocybin injections had their neural networks restored, with an added benefit of having stronger connections between different parts of the brain.
The Northeastern University-based researchers described their findings as “stunning.” The brains of all the rats showed elevated levels of phosphorylated tau proteins, which usually exist at high levels in people diagnosed with neurodegenerative conditions like Alzheimer’s, Parkinson’s disease and chronic encephalopathy.
In the rats given psilocybin, the volume of tau proteins kept decreasing as time elapsed after they received this treatment.
Additionally, all the rats were made to walk on a beam to test their mobility levels. The psilocybin group performed better than their counterparts that received a saline solution. This shows that the psilocybin treatment helped the rats to restore their mobility skills.
This study’s findings are significant because to-date, there isn’t any FDA-approved treatment for repeated TBIs. This is a concern, because data shows that almost 3 million people in America get diagnosed with a TBI each year. If psilocybin can prove in clinical trials that it can help to treat these individuals, there would be a huge door opened in the way traumatic brain injuries are treated. Effective TBI treatments would also forestall the complications that develop later as a result of suffering a traumatic brain injury.
Recent research has also shown that psilocybin can help to treat PTSD, chronic depression and several other mental health issues by boosting neuroplasticity. As more trials are conducted by firms like Seelos Therapeutics Inc. (NASDAQ: SEEL), psychedelic treatments will come closer to being approved for use in the mainstream medical field, especially for conditions that have proved to be hard to treat using conventional medications.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV…
The world’s first distributed psychedelic conference debuts with a global hybrid experience, 100+ speakers, 60+…
FDA grants NRx Pharmaceuticals approval of a Suitability Petition for single-patient preservative-free ketamine. The decision…
The FDA designation expands the drug’s potential patient pool tenfold, to an estimated 13 million…
NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from…
The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…